The emergence of the highly transmissible omicron subvariant XBB.1.5 should serve as a wake-up call for the U.S. to reinvest in new vaccines, therapeutics and surveillance efforts, Eric Topol, MD, founder and director of Scripps Research Translational Institute in San Diego, wrote in a Jan. 8 op-ed for The Washington Post.
Read the full post on Becker's Hospital Review - Healthcare News
